Q-omics provides the consensus-scored CNTD1 profile across patient tissues and cancer cell-line models. CNTD1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CNTD1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CNTD1 RNA expression shows 19,726 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where CNTD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNTD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNTD1 survival associations across molecular data types. CNTD1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNTD1 RNA expression–survival associations across cancer types. High CNTD1 expression shows unfavorable associations in KIRC, KIRP and ACC, but favorable associations in BLCA, BRCA and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CNTD1 RNA expression.
This table summarizes CNTD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CNTD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNTD1 shows lower tumor expression in KIRC and KICH and higher tumor expression in LIHC, BLCA, COAD and CHOL. The KIRC box plot shows higher CNTD1 RNA expression in normal versus tumor tissue (log2 FC = −0.897, t-test p < 0.001).
This table shows molecular features associated with CNTD1 in patient tissues and cancer cell lines. In patient samples, CNTD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CNTD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
